Peptide
Chonluten
SaveA Khavinson bioregulator tripeptide purported to normalize lung and bronchial mucosa function at the gene-expression level.
Quick verdict
Part of the Khavinson peptide series. Evidence limited to small Russian studies without international replication.
Evidence score
12/ 100
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Russian-language publications from the Khavinson group. No international peer-reviewed trials.
Benefits
- Claimed normalization of bronchial mucosa function
- Oral bioregulator peptide format
Dosage notes
Russian protocols: 5–10 mg/day orally for 10–30 day courses.
Side effects
- Not well characterized
- GI discomfort possible
Who should be cautious
Not approved outside Russia. Product quality from online sources is unverified.
What this page cannot tell you
Narrow evidence base from a single research group.
Leaderboard scores
- Immunity12
Write a review
Sign in to write a review.